179 related articles for article (PubMed ID: 37207587)
1. Targeted delivery of temozolomide by nanocarriers based on folic acid-hollow TiO
Uribe-Robles M; Ortiz-Islas E; Rodriguez-Perez E; Valverde FF; Lim T; Martinez-Morales AA
Biomater Adv; 2023 Aug; 151():213442. PubMed ID: 37207587
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells.
Dastghaib S; Shojaei S; Mostafavi-Pour Z; Sharma P; Patterson JB; Samali A; Mokarram P; Ghavami S
Cells; 2020 Oct; 9(11):. PubMed ID: 33105603
[TBL] [Abstract][Full Text] [Related]
3. Angiopep-2 Grafted PAMAM Dendrimers for the Targeted Delivery of Temozolomide:
Sahoo RK; Kumar H; Jain V; Sinha S; Ajazuddin ; Gupta U
ACS Biomater Sci Eng; 2023 Jul; 9(7):4288-4301. PubMed ID: 37307155
[TBL] [Abstract][Full Text] [Related]
4. Tri-block copolymer nanoparticles modified with folic acid for temozolomide delivery in glioblastoma.
Emamgholizadeh Minaei S; Khoei S; Khoee S; Karimi MR
Int J Biochem Cell Biol; 2019 Mar; 108():72-83. PubMed ID: 30660689
[TBL] [Abstract][Full Text] [Related]
5. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
[TBL] [Abstract][Full Text] [Related]
6. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
[TBL] [Abstract][Full Text] [Related]
7. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
[TBL] [Abstract][Full Text] [Related]
8. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
9. Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
Brunetti A; Marinelli O; Morelli MB; Iannarelli R; Amantini C; Russotti D; Santoni G; Maggi F; Nabissi M
Phytomedicine; 2019 Jan; 52():51-59. PubMed ID: 30599912
[TBL] [Abstract][Full Text] [Related]
10. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
11. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-cancer efficacy of multi-functionalized magnetite nanoparticles combining alternating magnetic hyperthermia in glioblastoma cancer cells.
Minaei SE; Khoei S; Khoee S; Vafashoar F; Mahabadi VP
Mater Sci Eng C Mater Biol Appl; 2019 Aug; 101():575-587. PubMed ID: 31029351
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
14. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
Kadhim ZA; Sulaiman GM; Al-Shammari AM; Khan RA; Al Rugaie O; Mohammed HA
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144488
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy.
Yasaswi PS; Shetty K; Yadav KS
J Control Release; 2021 Aug; 336():549-571. PubMed ID: 34229001
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
[TBL] [Abstract][Full Text] [Related]
19. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy.
Lee JE; Lim JH; Hong YK; Yang SH
Cancer Res Treat; 2018 Oct; 50(4):1331-1342. PubMed ID: 29334602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]